Diagnosis, treatment and preventive measures in congenital adrenal hyperplasia due to 21-hydroxylase deficiency in patients in adulthood

Abstract

In the article there are presented main approaches to the diagnosis, treatment and follow-up of patients with classical and nonclassical forms of 21-hydroxylase deficiency. The techniques of diagnostic tests and parameters of hormonal indices for the assessment of the adequacy of replacement therapy with glucocorticoids and mineralocorticoids are considered.

Keywords

congenital adrenal hyperplasia / nonclassical congenital adrenal hyperplasia / 17-OH-progesterone / sinakten

References

[1] Карева М.А., Чугунов И.С. Федеральные клинические рекомендации - протоколы по ведению пациентов с врожденной дисфункцией коры надпочечников в детском возрасте. Пробл. эндокринол. 2014; 60 (2): 42-50.

[2] Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2010; 95 (9): 4133-60.

[3] Speiser P.W., Dupont B., Rubinstein P., Piazza A., Kastelan A., New M.I. High frequency of nonclassical steroid 21-hydroxylase defi ciency. Am. J. Hum. Genet. 1985; 37: 650-67.

[4] Merke D.P., Bornstein S.R. Congenital adrenal hyperplasia. Lancet. 2005; 365: 2125-36.

[5] Azziz R., Hincapie L.A., Knochenhauer E.S., Dewailly D., Fox L., Boots L.R. Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study. Fertil. and Steril. 1999; 72: 915-25.

[6] Bidet M., Bellanne-Chantelot C., Galand-Portier M.B., Tardy V., Billaud L., Laborde K. et al. Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase defi ciency and 330 family members. J. Clin. Endocrinol. Metab. 2009; 94: 1570-8.

[7] Török D., Halasz Z., Garami M., Homoki J., Fekete G., Solyom J. Limited value of serum steroid measurements in identification of mild form of 21-hydroxylase deficiency. Exp. Clin. Endocrinol. Diabet. 2003; 111: 27-32.

[8] Riepe F.G., Krone N., Viemann M., Partsch C.J., Sippell W.G. Management of congenital adrenal hyperplasia: results of the ESPE questionnaire. Horm. Res. 2002; 58: 196-205.

[9] Brunton L.L., Lazo J.S., Parker K., Eds. The Pharmacological Basis of Therapeutics. McGraw Hill; 2005.

[10] Stikkelbroeck N.M., Oyen W.J., Van der Wilt G.J., Hermus A.R., Otten, B.J. Normal bone mineral density and lean body mass, but increased fat mass, in young adult patients with congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 2003; 88: 1036-42.

[11] Falhammar H., Filipsson H., Holmdahl G., Janson P., Nordenkskjöld A., Hagenfeld K. et al. Metabolic profile and body composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase defi ciency. J. Clin. Endocrinol. Metab. 2007; 92: 110-6.

[12] Zimmermann A., Grigorescu-Sido P., AlKhzouz C., Patberg K., Bucerzan S., Schulze E. et al. Alterations in lipid and carbohydrate metabolism in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase defi ciency. Horm. Res. Paediatr. 2010; 74 (1): 41-9.

[13] Bachelot A., Chakhtoura Z., Samara-Boustani D., Dulon J., Touraine P., Polak M. Bone health should be an important concern in the care of patients affected by 21 hydroxylase defi ciency. Int. J. Pediatr. Endocrinol. 2010; DOI: 10.11.1155/2010/326275.

[14] Barzon L., Sonino N., Fallo F., Palu G., Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol. 2003; 149: 273-85.

[15] Hague W.M., Adams J., Rodda C., Brook C.G., de Bruyn R., Grant D.B. et al. The prevalence of polycystic ovaries in patients with congenital adrenal hyperplasia and their close relatives. Clin. Endocrinol. (Oxf.). 1990; 33: 501-10.

[16] Hagenfeldt K., Janson P.O., Holmdahl G., Falhammar H., Filipsson H., Frisen L. et al. Fertility and pregnancy outcome in women with congenital adrenal hyperplasia due to 21-hydroxylase defi ciency. Hum. Reprod. 2008; 23: 1607-13.

[17] Файзулин А.К., Батыгин М.П., Глыбина Т.М., Шкитырь З.В. Современные методы хирургической коррекции пороков наружных гениталий у девочек с врожденной дисфункцией коры надпочечников. Андрология и генитальная хирургия. 2011;(3): 69-73.

[18] Casteras A., De Silva P., Rumsby G., Conway G.S. Reassessing fecundity in women with classical congenital adrenal hyperplasia (CAH): normal pregnancy rate but reduced fertility rate. Clin. Endocrinol. (Oxf.). 2009; 70: 833-7.

[19] Lo J.C., Schwitzgebel V.M., Tyrrell J.B., Fitzgerald P.A., Kaplan S.L., Conte F.A. et al. Normal female infants born of mothers with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 1999; 84: 930-6.

[20] Дедов И.И., Краснопольский В.И., Сухих Г.Т. Российский национальный консенсус «Гестационный сахарный диабет: диагностика, лечение, послеродовое наблюдение». Сахарный диабет. 2012;15 (4): 4-10.

[21] Bidet M., Bellanné-Chantelot C., Galand-Portier M.B., Golmard J.L., Tardy V., Morel Y. et al. Fertility in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 2010; 95: 1182-90.

[22] Martin K.A., Chang R.J., Ehrmann D.A., Ibanez L., Lobo R.A., Rosenfi eld R.L. et al. Swiglo evaluation and treatment of hirsutism in premenopausal women: An endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2008; 93 (4): 1105-20.

[23] Moran C., Azziz R., Weintrob N., Witchel S.F., Rohmer V., Dewailly D. et al. Reproductive outcome of women with 21-hydroxylasedeficient nonclassic adrenal hyperplasia. J. Clin. Endocrinol. Metab. 2006; 91: 3451-6.

RIGHTS & PERMISSIONS

Eco-Vector